The burden of illness associated with hepatocellular carcinoma in the United States.

[1]  Hegang Chen,et al.  Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. , 2006, Journal of the National Medical Association.

[2]  W. Lawrence,et al.  Burden of illness in cancer survivors: findings from a population-based national sample. , 2004, Journal of the National Cancer Institute.

[3]  D. Veenstra,et al.  Trends in expenditures for Medicare liver transplant recipients , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  M. Rizzetto.  Hepatocellular carcinoma: screening and therapy. , 2000, Minerva gastroenterologica e dietologica.

[5]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[6]  R. D. de Man,et al.  Resection of Extrahepatic Hepatocellular Carcinoma Metastasis can result in Long-term Survival , 2005, Acta Chirurgica Belgica.

[7]  J. Glaspy.  Therapeutic options in the management of renal cell carcinoma. , 2002, Seminars in oncology.

[8]  M. Yuen,et al.  Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Hall,et al.  Primary prevention of hepatocellular carcinoma in developing countries. , 2000, Mutation research.

[10]  P. Parrilla,et al.  Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? , 2003, Transplantation Proceedings.

[11]  B. le Bail,et al.  Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. , 2005, Journal of the American College of Surgeons.

[12]  Ching-Lung Lai,et al.  Natural history of hepatitis-related hepatocellular carcinoma. , 2008, World journal of gastroenterology.

[13]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[14]  Y. Maehara,et al.  Liver transplantation for hepatocellular carcinoma. , 2008, Journal of hepato-biliary-pancreatic surgery.

[15]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[16]  N Urban,et al.  Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. , 1995, Journal of the National Cancer Institute.

[17]  K. McGlynn,et al.  A Comparison of Trends in the Incidence of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.

[18]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[19]  S G Pauker,et al.  Screening for prostate cancer. A decision analytic view. , 1994, JAMA.

[20]  U. Ladabaum,et al.  Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  D. Manninen,et al.  An economic analysis of liver transplantation. Costs, insurance coverage, and reimbursement. , 1993, Gastroenterology clinics of North America.

[22]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Therneau,et al.  Mortality and hospital utilization for hepatocellular carcinoma in the United States. , 2005, Gastroenterology.

[24]  R. Kessler,et al.  The Effects of Chronic Medical Conditions on Work Loss and Work Cutback , 2001, Journal of occupational and environmental medicine.

[25]  J B Wong,et al.  Cost-effectiveness of treatments for chronic hepatitis C. , 1999, The American journal of medicine.

[26]  C. Somkin,et al.  Cost of Care for Cancer in a Health Maintenance Organization , 1997, Health care financing review.

[27]  W. Tierney,et al.  The use of an electronic patient record system to identify advanced cancer patients and antidepressant drug use. , 1999, Journal of palliative medicine.

[28]  W. Crown,et al.  Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  F. Vargas‐Vorácková,et al.  In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective? , 2004, Annals of hepatology.

[30]  Ruth Etzioni,et al.  Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.

[31]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[32]  A. Neugut,et al.  Predictors of survival after hepatic resection among patients with colorectal liver metastasis , 2007, British Journal of Cancer.

[33]  Rice Dp,et al.  Estimating the cost of illness. , 1967 .

[34]  Yoshiyuki Suzuki,et al.  Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[35]  G. Sanders,et al.  Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C , 2004, Alimentary pharmacology & therapeutics.

[36]  D. Häussinger,et al.  [Hepatocellular carcinoma: rising incidence of hepatitis C virus-associated cases at a university clinic in Germany]. , 2002, Deutsche medizinische Wochenschrift.

[37]  H. Bismuth,et al.  Liver Transplantation for Hepatocellular Carcinoma , 1999, Seminars in liver disease.

[38]  H. El‐Serag.  Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.

[39]  J. Bruix,et al.  Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. , 2001, Hepatology.

[40]  T. Cooper.  Department of Health, Education, and Welfare. , 1976, Military medicine.

[41]  V. Chen,et al.  Screening for Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis: A Cost-Utility Analysis , 2003, American Journal of Gastroenterology.

[42]  D. Budman,et al.  A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Sethuraman,et al.  The use of dietary supplements by veterans with cancer. , 2004, Journal of alternative and complementary medicine.

[44]  I. Durand-zaleski,et al.  Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost. , 2006, Gastroenterologie clinique et biologique.

[45]  S. Stuver,et al.  Towards global control of liver cancer? , 1998, Seminars in cancer biology.

[46]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[47]  J. Lightwood,et al.  Pancreatic cancer: Total costs and utilization of health services , 1999, Journal of surgical oncology.

[48]  J. Goodwin,et al.  Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results. , 1999, Journal of clinical epidemiology.

[49]  G. Oster,et al.  Opioid use and health care charges at the end of life in patients with metastatic cancer. , 2004, Managed care interface.

[50]  T. Wilt,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.